Gynthersen, Rosa Maja Møhring
Hansen, Mette Frimodt
Ocias, Lukas Frans
Kjaer, Andreas
Petersen, Randi Føns
Ostrowski, Sisse Rye
Harritshøj, Lene
Jacobsen, Søren
Overgaard, Ulrik
Krogfelt, Karen Angeliki
Lebech, Anne-Mette
Mens, Helene
Funding for this research was provided by:
Interreg North-West Europe (38-2-7-19, 38-2-7-19)
Danish National Research Foundation (126)
GlaxoSmithKline foundation
Pfizer
Gilead
Article History
Received: 28 October 2022
Accepted: 3 March 2023
First Online: 20 March 2023
Declarations
:
: The research was performed in accordance with the Declaration of Helsinki and the study protocol was approved by the Danish Regional Ethical Committee of the Capital Region (Region Hovedstaden) (j.no. H-20009322) and the Danish Data Protection Agency (approval no. P-2021-364). The patients with a blood sample with detectable <i>N. mikurensis</i> DNA were contacted by their treating physician to obtain written consent for the publication of clinical data and for us to contact them.
: The authors affirm that the three participants described in Table InternalRef removed have provided informed consent for publication of data included.
: Anne-Mette Lebech reports speakers’ honorarium/travel grants/Advisory board activity from Gilead, speakers honorarium /travel grants from GSK, speaker’s honorarium/advisory board activity from Pfizer. Anne-Mette Lebech is supported by a grant from The Lundbeck Foundation. The other authors report no competing interests.